A Prospective, Open, Self-controlled Study of the Effects of Chiglitazar Sodium on Glucose and Lipid Metabolism in Patients With Type 2 Diabetes Mellitus (T2DM)

• Status: Not yet recruiting
• Trial end date: 2025-12-30

Summary

The goal of this clinical trial is to learn about inour study aimed to evaluate serum lipid profiles of T2DM patients before and after Chiglitazar Sodium administration.

The main question[s] it aims to answer are:

• Quantitative lipidomics information enables in-depth analysis of lipids and can reveal Chiglitazar Sodium-specific lipid metabolic patterns, thereby strengthening lipidomics as a promising tool for exploring the molecular mechanisms of T2DM.

• It can also be applied to other T2DM lipidomics studies to better understand lipid metabolism patterns and integration with other omics measures.

• Phase: N/A

Details

• Lead Sponsor: Yufan Wang